Publikation
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
Wissenschaftlicher Artikel/Review - 01.03.2009
Marre M, Colagiuri S, Le Thi T D, Zdravkovic M, Strand J, Kamaruddin N A, Bebakar W M W, Brändle Michael, Shaw J, LEAD-1 SU study group
Marre, M
2
0
Shaw, J
1
0
Brändle, Michael
ChefarztAllgemeine Innere Medizin | Hausarztmedizin und Notfallmedizin, Endokrinologie | Diabetologie | Osteologie | Stoffwechselerkrankungen · Dept. I
141
21
Bebakar, W M W
1
0
Kamaruddin, N A
1
0
Strand, J
1
0
Zdravkovic, M
1
0
Le Thi, T D
1
0
Colagiuri, S
1
0
LEAD-1 SU study group,
1
0